Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRBP OTCMKTS:NXEN OTCMKTS:OREXQ NASDAQ:VRPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsNXENNexien Biopharma$0.01$0.01$0.00▼$0.05$403K-0.792,371 shsN/AOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsVRPXVirpax Pharmaceuticals$0.42+16.3%$0.28$0.13▼$60.25$522K1.58153,130 shs42,123 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRBPKiromic BioPharma0.00%0.00%0.00%0.00%-89.50%NXENNexien Biopharma0.00%0.00%0.00%-36.67%-67.61%OREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%VRPXVirpax Pharmaceuticals+16.34%+23.53%+73.55%+64.06%-98.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVRPXVirpax Pharmaceuticals1.5021 of 5 stars3.03.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRBPKiromic BioPharma 0.00N/AN/AN/ANXENNexien Biopharma 0.00N/AN/AN/AOREXQOrexigen Therapeutics 0.00N/AN/AN/AVRPXVirpax Pharmaceuticals 2.00Hold$75.0017,757.14% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/ANXENNexien BiopharmaN/AN/AN/AN/A($0.01) per shareN/AOREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞VRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/ANXENNexien Biopharma-$240KN/A0.00∞N/AN/AN/A-4,015.59%N/AOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/AVRPXVirpax Pharmaceuticals-$15.19MN/A0.00∞N/AN/A-1,554.34%-338.29%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRBPKiromic BioPharmaN/AN/AN/AN/AN/ANXENNexien BiopharmaN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRBPKiromic BioPharmaN/A0.160.22NXENNexien BiopharmaN/A0.020.02OREXQOrexigen TherapeuticsN/AN/AN/AVRPXVirpax PharmaceuticalsN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRBPKiromic BioPharma10.91%NXENNexien BiopharmaN/AOREXQOrexigen TherapeuticsN/AVRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipKRBPKiromic BioPharma20.59%NXENNexien Biopharma30.60%OREXQOrexigen Therapeutics13.30%VRPXVirpax Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableNXENNexien Biopharma470.77 million49.12 millionNot OptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionableVRPXVirpax Pharmaceuticals71.24 million4.71 millionNot OptionableOREXQ, NXEN, VRPX, and KRBP HeadlinesRecent News About These CompaniesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comVirpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comVirpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using METMarch 11, 2025 | msn.comVirpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology ConferenceMarch 11, 2025 | msn.comVirpax Looking to Use MET to Develop Intranasal COVID VaccineMarch 7, 2025 | businesswire.comAnalysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)March 6, 2025 | markets.businessinsider.comVirpax’s NES100 to be Presented at The Society of Toxicology by NCATSMarch 5, 2025 | finance.yahoo.comVirpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope TechnologyMarch 3, 2025 | msn.comVirpax lauds Nanomerics’ MET study with no severe side effectsMarch 1, 2025 | investing.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | finance.yahoo.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | businesswire.comVirpax Confirms Positive Results with US Army with Probudur™ for Combat Care StudyFebruary 13, 2025 | joplinglobe.comJVirpax Pharmaceuticals confirms results with U.S. Army with ProbudurFebruary 13, 2025 | markets.businessinsider.comVirpax reports positive study results for pain management drugFebruary 13, 2025 | msn.comVirpax Pharmaceuticals appoints new independent directorFebruary 6, 2025 | msn.comNew MarketBeat Followers Over TimeOREXQ, NXEN, VRPX, and KRBP Company DescriptionsKiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Nexien Biopharma OTCMKTS:NXEN$0.0057 0.00 (0.00%) As of 07/15/2025Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.Orexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Virpax Pharmaceuticals NASDAQ:VRPX$0.42 +0.06 (+16.34%) As of 07/16/2025 03:52 PM EasternVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
